CPT code 48102 represents a percutaneous, image-guided pancreatic needle biopsy with tissue sent for pathological analysis. This procedure is clinically important for diagnosing pancreatic masses, distinguishing malignant from benign lesions, and guiding oncologic and surgical management. Nationally, accurate coding for percutaneous pancreatic biopsy affects care documentation, appropriate utilization of interventional radiology resources, and proper claims processing across public and commercial payers.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary addresses coverage and coding consistency among these major payers and highlights the clinical context for use of the code.

Readers will find a concise review of the clinical indication and typical care setting for 48102, common billing considerations, and the types of benchmarks and policy updates relevant to this service. The content provides guidance on where the procedure is typically performed, how it is recorded for pathology follow-up, and what to expect in payers’ administrative handling. Data not available in the input is noted where payer-specific coverage policies, associated taxonomies, and ICD-10 pairings would normally appear.